FirstIgnite is supporting the commercialization of Johns Hopkins University Applied Physics Laboratory’s linker molecules for bisconjugation technology. This technology involves using a novel linker molecule to connect proteins to supports or small molecules. There are numerous advantages to this technology, including a low cost, 3-step manufacturing process, the ability to work with a wide range of proteins, increased protein activity compared to commercially available linkers, and robustness under acidic conditions. Additionally, this technology is highly effective and does not wash off supports.

With its wide range of applications, this technology has potential in various industries, including affinity chromatography for monoclonal antibody purification, cancer treatments, tumor identification, and paintable proteins. The global cancer therapeutics market is expected to reach $335.06 billion by 2029, up from $166.5 billion in 2021.

Johns Hopkins University Applied Physics Laboratory’s linker molecules for bisconjugation technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Johns Hopkins University team, you can schedule a time directly on their team’s calendar here.